Access through your institution Buy or subscribe Acute myeloid leukemia (AML) is a heterogeneous hematologic disease characterized by the accumulation of immature myeloid cells. Despite the

recent advances in the treatment of AML, drug resistance and disease relapse remain a substantial clinical problem. AML cells are characterized by their recurrent contact with the stromal

microenvironment in the bone marrow (BM).1 This interplay between the BM stroma and AML cells protects malignant cells from spontaneous apoptosis, promotes proliferation and drug resistance.

Increasing evidence suggests that this stromal refuge has a pivotal role in paving the way for disease relapse. This is a preview of subscription content, access via your institution ACCESS

institutional subscriptions * Read our FAQs * Contact customer support REFERENCES * Ayala F, Dewar R, Kieran M, Kalluri R . Contribution of bone microenvironment to leukemogenesis and

leukemia progression. _Leukemia_ 2009; 23: 2233–2241. Article  CAS  Google Scholar  * Uy GL, Rettig MP, Motabi IH, McFarland K, Trinkaus KM, Hladnik LM _et al_. A phase 1/2 study of

chemosensitization with the CXCR4 antagonist plerixafor in relapsed or refractory acute myeloid leukemia. _Blood_ 2012; 119: 3917–3924. Article  CAS  Google Scholar  * Tavor S, Petit I,

Porozov S, Avigdor A, Dar A, Leider-Trejo L _et al_. CXCR4 regulates migration and development of human acute myelogenous leukemia stem cells in transplanted NOD/SCID mice. _Cancer Res_

2004; 64: 2817–2824. Article  CAS  Google Scholar  * Hanahan D, Weinberg RA . Hallmarks of cancer: the next generation. _Cell_ 2011; 144: 646–674. Article  CAS  Google Scholar  * Chen WL,

Wang JH, Zhao AH, Xu X, Wang YH, Chen TL _et al_. A distinct glucose metabolism signature of acute myeloid leukemia with prognostic value. _Blood_ 2014; 124: 1645–1654. Article  CAS  Google

Scholar  * Akers LJ, Fang W, Levy AG, Franklin AR, Huang P, Zweidler-McKay PA . Targeting glycolysis in leukemia: a novel inhibitor 3-BrOP in combination with rapamycin. _Leuk Res_ 2011; 35:

814–820. Article  CAS  Google Scholar  * Xu RH, Pelicano H, Zhou Y, Carew JS, Feng L, Bhalla KN _et al_. Inhibition of glycolysis in cancer cells: a novel strategy to overcome drug

resistance associated with mitochondrial respiratory defect and hypoxia. _Cancer Res_ 2005; 65: 613–621. CAS  PubMed  Google Scholar  * Samudio I, Fiegl M, McQueen T, Clise-Dwyer K, Andreeff

M . The warburg effect in leukemia-stroma cocultures is mediated by mitochondrial uncoupling associated with uncoupling protein 2 activation. _Cancer Res_ 2008; 68: 5198–5205. Article  CAS

  Google Scholar  * Garrido SM, Appelbaum FR, Willman CL, Banker DE . Acute myeloid leukemia cells are protected from spontaneous and drug-induced apoptosis by direct contact with a human

bone marrow stromal cell line (HS-5). _Exp Hematol_ 2001; 29: 448–457. Article  CAS  Google Scholar  * Tamada M, Nagano O, Tateyama S, Ohmura M, Yae T, Ishimoto T _et al_. Modulation of

glucose metabolism by CD44 contributes to antioxidant status and drug resistance in cancer cells. _Cancer Res_ 2012; 72: 1438–1448. Article  CAS  Google Scholar  * Chen C, Liu Y, Liu R,

Ikenoue T, Guan KL, Liu Y _et al_. TSC-mTOR maintains quiescence and function of hematopoietic stem cells by repressing mitochondrial biogenesis and reactive oxygen species. _J Exp Med_

2008; 205: 2397–2408. Article  CAS  Google Scholar  * Zeng Z, Shi YX, Tsao T, Qiu Y, Kornblau SM, Baggerly KA _et al_. Targeting of mTORC1/2 by the mTOR kinase inhibitor PP242 induces

apoptosis in AML cells under conditions mimicking the bone marrow microenvironment. _Blood_ 2012; 120: 2679–2689. Article  CAS  Google Scholar  * Spoo AC, Lubbert M, Wierda WG, Burger JA .

CXCR4 is a prognostic marker in acute myelogenous leukemia. _Blood_ 2007; 109: 786–791. Article  CAS  Google Scholar  * Dillenburg-Pilla P, Patel V, Mikelis CM, Zarate-Blades CR, Doci CL,

Amornphimoltham P _et al_. SDF-1/CXCL12 induces directional cell migration and spontaneous metastasis via a CXCR4/Galphai/mTORC1 axis. _FASEB J_ 2015; 29: 1056–1068. Article  CAS  Google

Scholar  * Vander Heiden MG, Cantley LC, Thompson CB . Understanding the Warburg effect: the metabolic requirements of cell proliferation. _Science_ 2009; 324: 1029–1033. Article  CAS 

Google Scholar  Download references ACKNOWLEDGEMENTS MQ was supported by the IZKF Erlangen. RJ was supported by the ELAN program of the University of Erlangen. FAK was supported by the EC

FP7-funded project RADIANT. DM was supported by the IZKF Erlangen and the Max-Eder program of the Deutsche Krebshilfe. We acknowledge the assistance of the Core Unit Cell Sorting and

Immunomonitoring Erlangen. AUTHOR CONTRIBUTIONS MB performed research, analyzed data and helped writing the manuscript. MQ, MB, FK, DS and WH performed research and analyzed data. MA

collected patient material and provided patient data. AM provided patient material and helped writing the manuscript. RJ performed research, helped designing the study and writing the

manuscript. DM designed the study, analyzed data and wrote the manuscript. AUTHOR INFORMATION AUTHORS AND AFFILIATIONS * Department of Internal Medicine 5, Hematology and Oncology,

University of Erlangen-Nuremberg, Erlangen, Germany M Braun, M Qorraj, D Saul, M Aigner, A Mackensen, R Jitschin & D Mougiakakos * Department of Nephropathology, Institute of Pathology,

University of Erlangen-Nuremberg, Erlangen, Germany M Büttner * European Molecular Biology Laboratory (EMBL), Heidelberg, Germany F A Klein & W Huber Authors * M Braun View author

publications You can also search for this author inPubMed Google Scholar * M Qorraj View author publications You can also search for this author inPubMed Google Scholar * M Büttner View

author publications You can also search for this author inPubMed Google Scholar * F A Klein View author publications You can also search for this author inPubMed Google Scholar * D Saul View

author publications You can also search for this author inPubMed Google Scholar * M Aigner View author publications You can also search for this author inPubMed Google Scholar * W Huber

View author publications You can also search for this author inPubMed Google Scholar * A Mackensen View author publications You can also search for this author inPubMed Google Scholar * R

Jitschin View author publications You can also search for this author inPubMed Google Scholar * D Mougiakakos View author publications You can also search for this author inPubMed Google

Scholar CORRESPONDING AUTHOR Correspondence to D Mougiakakos. ETHICS DECLARATIONS COMPETING INTERESTS The authors declare no conflict of interest. ADDITIONAL INFORMATION Supplementary

Information accompanies this paper on the Leukemia website SUPPLEMENTARY INFORMATION SUPPLEMENTARY INFORMATION (DOCX 795 KB) RIGHTS AND PERMISSIONS Reprints and permissions ABOUT THIS

ARTICLE CITE THIS ARTICLE Braun, M., Qorraj, M., Büttner, M. _et al._ CXCL12 promotes glycolytic reprogramming in acute myeloid leukemia cells via the CXCR4/mTOR axis. _Leukemia_ 30,

1788–1792 (2016). https://doi.org/10.1038/leu.2016.58 Download citation * Published: 08 March 2016 * Issue Date: August 2016 * DOI: https://doi.org/10.1038/leu.2016.58 SHARE THIS ARTICLE

Anyone you share the following link with will be able to read this content: Get shareable link Sorry, a shareable link is not currently available for this article. Copy to clipboard Provided

by the Springer Nature SharedIt content-sharing initiative